euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary Q4 and full-year 2008 results

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

9-month report

02.03.2009

» Increased profitability and strong financial position for full-year
2008 » Excellent progress in late-stage pipeline products » Vaccine
to prevent Japanese Encephalitis approved in Australia

Vienna (Austria), March 2, 2009 - Today, the biotech-vaccine company
Intercell AG (VSE: ICLL) announced its preliminary financial results
for the fourth quarter and the full financial year 2008, and
presented an update on the Company's development programs.

Driven by strong revenues of EUR 30.5 m in the fourth quarter and
income tax effects, Intercell´s profit for the full year 2008 was EUR
17.2 m, compared to EUR 5.0 m in the prior year. The annual revenues
increased from EUR 53.3 m in the year ended December 31, 2007 to EUR
55.8 m in the year ended December 31, 2008. R&D costs for the full
year 2008 increased to EUR 56.1 m and enabled the strong progression
of Intercell's late-stage pipeline, including the advanced clinical
programs acquired with Iomai Corporation. Cash and marketable
securities of EUR 190.9 m at year-end give Intercell a strong
financial position and will allow aggressive investment in late-stage
pipeline products.

Intercell's vaccine to prevent Japanese Encephalitis, IXIARO®,
received positive CHMP opinion in Europe and product approval in
Australia, with U.S. approval expected in the near future. No
additional requests or comments from the authorities are pending;
hence the remaining administrative steps are expected to be concluded
soon. "We have successfully managed to market our first vaccine and
therefore reached one of the most important milestones in the
Company's history - Intercell has proven its ability to develop and
produce a product for global markets. With this achievement, we are
looking forward to initiating a new growth phase for our company,"
said Intercell Chief Executive Officer Gerd Zettlmeissl.

DEVELOPMENT PROGRAMS AND PRODUCT PIPELINE

Aggressive investment in four late-stage pipeline products with
clinical efficacy results expected within the next 12 months for
Travelers Diarrhea vaccine patch, Staphylococcus aureus (S. aureus)
vaccine candidate, and Pseudomonas vaccine candidate and Pandemic
Influenza

» Traveler's Diarrhea patch vaccine - Recruitment of pivotal Phase
III has begun and initiation of Phase III clinical trial planned
for traveling season in H1 2009

» S. aureus vaccine - Merck & Co., Inc. has advanced the clinical
efficacy trial in cardiothoracic surgery patients and efficacy data
is expected mid 2009. The program was expanded with an additional
Phase II study in hemodialysis patients with late-stage kidney
disease

» Pseudomonas aeruginosa vaccine - Phase II clinical trial in
mechanically ventilated intensive care patients has been initiated-
First efficacy data is expected H2 2009

» Pandemic Influenza Vaccine Enhancement Patch - Program has been
granted additional funding of USD 12.5 m by U.S. Department of
Health and Human Services (HHS) - Start of Phase II is planned for
H1 2009

» Streptococcus pneumoniae vaccine - Phase I clinical trial start
with vaccine candidate to prevent infections with the bacterium
Streptococcus pneumoniae is planned for March 2009

» herapeutic Hepatitis C vaccine - Initiation of next clinical trials
will take advantage of a combination treatment and the use of IC31®
as more potent adjuvant - strategic partnering process ongoing

» Tuberculosis vaccine - Phase I/II clinical development program of
Statens Serum Institut (SSI), Intercell and Sanofi Pasteur is
proceeding according to plan

» Group B Streptococcus vaccine - program has been licensed to
Novartis

KEY FINANCIAL INFORMATION

in EUR thousands
Year ended December 31,
2008 2007 2006

Revenues 55,763 53,349 23,452

Net profit/(loss) 17,175 5,009 (16,143)

Net operating cash flow (10,186) 41,686 (7,979)

Cash and marketable

securities, end of the
year 190,865 287,571 94,421

For the full report please visit www.intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market